Evidence from animal models also suggests that CGA can stimulate GLP-1 under certain conditions; for example, Sharma et al. [32] administered 50 mg/kg of CGA to mice with rotenone-induced Parkinson’s disease for 13 weeks. The gene discussed is GLP1R; the disease is Parkinson disease.